A Safety and Effectiveness Study of JUVÉDERM VOLIFT® XC Versus Control for Moderate to Severe Nasolabial Folds
Launched by ALLERGAN · Oct 30, 2013
Trial Information
Current as of July 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 2 visible moderate to severe nasolabial folds
- • Agree to refrain from undergoing other anti-wrinkle/volumizing treatments in the lower two-thirds of the face for the duration of the study
- Exclusion Criteria:
- • Undergone facial tissue augmentation with dermal fillers in the lower two-thirds of the face within the past 12 months
- • Undergone facial tissue augmentation with fat injections, botulinum toxin injections in the lower two-thirds of the face, mesotherapy, or cosmetic facial procedures in the face or neck within the past 6 months
- • Received semi-permanent fillers or permanent facial implants anywhere in the lower face
About Allergan
Allergan, a global leader in pharmaceutical innovation, specializes in developing and commercializing a diverse portfolio of advanced therapeutic and aesthetic products. With a commitment to improving the health and well-being of patients, Allergan conducts rigorous clinical trials to evaluate the safety and efficacy of its therapies across various medical fields, including ophthalmology, dermatology, and neuroscience. The company is dedicated to adhering to the highest ethical standards and regulatory guidelines, ensuring that its research not only advances medical science but also meets the needs of healthcare providers and patients worldwide. Through strategic collaborations and a focus on scientific excellence, Allergan continues to drive advancements in treatment options and enhance patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Chicago, Illinois, United States
San Francisco, California, United States
West Palm Beach, Florida, United States
Los Angeles, California, United States
Coral Gables, Florida, United States
Birmingham, Alabama, United States
Coral Gables, Florida, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials